RGNX vs. CRGX, RLAY, IMTX, MESO, HLVX, PRME, NVAX, EXAI, AUTL, and CABA
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include CARGO Therapeutics (CRGX), Relay Therapeutics (RLAY), Immatics (IMTX), Mesoblast (MESO), HilleVax (HLVX), Prime Medicine (PRME), Novavax (NVAX), Exscientia (EXAI), Autolus Therapeutics (AUTL), and Cabaletta Bio (CABA). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO (NASDAQ:RGNX) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.
CARGO Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -291.99%. CARGO Therapeutics' return on equity of 0.00% beat REGENXBIO's return on equity.
REGENXBIO presently has a consensus price target of $38.45, suggesting a potential upside of 130.68%. CARGO Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 45.57%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than CARGO Therapeutics.
In the previous week, REGENXBIO had 5 more articles in the media than CARGO Therapeutics. MarketBeat recorded 6 mentions for REGENXBIO and 1 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 0.55 beat REGENXBIO's score of -0.27 indicating that CARGO Therapeutics is being referred to more favorably in the news media.
REGENXBIO received 418 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 65.79% of users gave REGENXBIO an outperform vote.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 1.4% of CARGO Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
CARGO Therapeutics has lower revenue, but higher earnings than REGENXBIO.
Summary
CARGO Therapeutics beats REGENXBIO on 8 of the 14 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
